Multilingual Nordic packages against availability problems

The Nordic region – five countries, 27 million inhabitants, five official languages. Multilingual Nordic packages are an important option for making medicines available in as many countries in the Nordic region as possible. 

Availability of medicines is a hot topic across Europe. As regards marketing authorisations and packages, Nordic cooperation is increasingly becoming a necessity. 

New, innovative medicines may be intended for conditions which affect such small numbers of patients in individual countries that bringing the product to market would not be cost-effective. Nordic packages could be the answer. Nordic packages often reduce the costs of pharmaceutical companies even regarding medicines intended for larger patient groups. They also provide flexibility in the face of logistic and production-related challenges. 

The Nordic regulatory authorities have gathered the guidelines for medicine packages in a single document, and published a comprehensive questions and answers document. In addition, the procedure for common Nordic assessment of labelling texts introduced in 2014 is also working well. Common assessment by two or more Nordic countries makes it possible for marketing authorisation holders to receive the comments of all countries involved at the same time, with the authorities having already settled any conflicts between different countries. 

It is pleasing to note that all the five countries in the Nordic region can agree on consistent guidelines for an increasing number of package-related issues. Finding a common position has required a great degree of collaboration and discussion between the Nordic regulatory authorities over the past few years. In modern society, English text on packages could also be a useful addition. 

Clear guidelines and practical assessment procedures are, and will continue to be, key in ensuring the availability of medicines. It is often possible to include several languages on a package, especially if the issue is addressed sufficiently early during the procedure. Nordic packages are an option worth considering – if you need help with planning and the overall procedure, PharmaLex regulatory experts will be happy to help. 


This blog is intended to communicate PharmaLex’s capabilities which are backed by the author’s expertise. However, PharmaLex US Corporation and its parent, Cencora, Inc., strongly encourage readers to review the references provided with this article and all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto as the article may contain certain marketing statements and does not constitute legal advice. 

Contact us for more information

Scroll to Top